期刊档案 · PHARMACOLOGY & PHARMACY
International Journal of Pharmaceutics-X
ISSN 2590-1567 · Elsevier · Netherlands · Continuous publication · 创刊 2019
International Journal of Pharmaceutics-X 中科院 医学 2区（2025 年升级版），影响因子 7.97，完全开放获取，APC 约 2,660 美元，近 24 个月 103 篇文章投稿到接收中位 72 天，2025 年发文 164 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
International Journal of Pharmaceutics-X 由 Elsevier 出版，属中科院医学大类（2025 升级版2区）。按 OpenAlex 近年发文统计，该刊主要发表 Advanced Drug Delivery Systems、Drug Solubulity and Delivery Systems、Advancements in Transdermal Drug Delivery 等主题的论文，这 3 个主题约占 32.1%，主导子领域为 Pharmaceutical Science、Molecular Biology。（根据 OpenAlex 主题统计与中科院分区数据生成）
International Journal of Pharmaceutics: X offers authors with high-quality research who want to publish in a gold open access journal the opportunity to make their work immediately, permanently, and freely accessible.International Journal of Pharmaceutics: X authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright. Please check the APC here. The journal is indexed in SCOPUS, PUBMED, PMC and DOAJ.The International Journal of Pharmaceutics is the second most cited journal in the "Pharmacy & Pharmacology" category out of 358 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.Editorial Policy The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：PHARMACOLOGY & PHARMACY
主编 Juergen Siepmann出版商官网
编委会国家分布：中国大陆 7 位（约 5%）；主要国家 美国 24、英国 21、意大利 14、日本 9、德国 8（共 133 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics11.2%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics10.9%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics10%
- Nanoparticle-Based Drug DeliveryMaterials Science9.6%
- Nanoplatforms for cancer theranosticsEngineering9.5%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology5.5%
- 3D Printing in Biomedical ResearchEngineering4.5%
- Protein purification and stabilityBiochemistry, Genetics and Molecular Biology3.3%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 1 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 1 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
PMCPubMed出版商官网
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 7.97LetPub ·
- 影响因子（出版商公布）
- 7.9出版商官网 ·
- CiteScore 2026-06
- 8.9LetPub ·
- CiteScore（出版商公布）
- 8.9出版商官网 ·
- SJR 2026-06
- 1.1LetPub ·
- SNIP 2026-06
- 1.46LetPub ·
- h-index
- 39OpenAlex ·
- i10-index
- 195OpenAlex ·
- 两年平均被引
- 3.58OpenAlex ·
- 自引率
- 2.5%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 149LetPub ·
逐年发文量 OpenAlex 统计 · 累计 662 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 195 | 195 | 57 |
| 2025 | 164 | 164 | 517 |
| 2024 | 87 | 87 | 1,023 |
| 2023 | 67 | 67 | 1,234 |
| 2022 | 44 | 44 | 909 |
| 2021 | 38 | 38 | 865 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
72 天投稿到接收中位数 · P25–P75 54 天 – 95 天
- 接收到上线
- 中位数 1 天（103 篇）
- 投稿到上线
- 中位数 75 天
- 样本
- 103 篇有投稿与接收日期的文章（窗口内共 401 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 期刊官网数据：平均Submission to first decision: 2 days; Submission to decision after review: 30 days; Submission to acceptance: 88 days; Acceptance to online publication: 3 days;网友分享经验：17 WeeksLetPub ·
- 投稿到首次决定
- 2 天出版商官网 ·
- 外审后首次决定
- 29 天出版商官网 ·
- 投稿到接收
- 82 天出版商官网 ·
- 接收到发表
- 2 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 17 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,660 | 有 | CC BY、CC BY-NC、CC BY-NC-ND | |
| OpenAlex | USD 2,590 / EUR 2,420 / GBP 2,070 / JPY 321,240 | — | — | |
| LetPub | USD 2,790 | 有 | — | |
| 出版商官网 | USD 2,880 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
接收的文章类型4 种
- full length manuscriptsFull Length Manuscripts未说明篇幅
- reviewFull Length ManuscriptsReviews and Mini-ReviewsSuggestions for review articles will be considered by the Review Editor. "Mini-reviews" of a topic are especially…未说明篇幅
- review articleFull Length ManuscriptsReviews and Mini-ReviewsSuggestions for review articles will be considered by the Review Editor. "Mini-reviews" of a topic are especially…未说明篇幅
- reviews and mini-reviewsReviews and Mini-Reviews Suggestions for review articles will be considered by the Review Editor. "Mini-reviews" of a topic are especially welcome.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 许可与版权 License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
single anonymized review process 模型摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
preprint sharing allowed 模型摘要
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- 出版国家或地区
- Netherlands
- 出版语言
- English
- 出版周期
- Continuous publication
- 创刊年份
- 2019
- ISSN
- 2590-1567
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 International Journal of Pharmaceutics-X 的常见问题
International Journal of Pharmaceutics-X 是中科院几区期刊？
2025 年升级版分区表中，International Journal of Pharmaceutics-X 为医学 2区，小类 药学 1 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。
International Journal of Pharmaceutics-X 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 7.97，CiteScore 为 8.9，h-index 为 39。
International Journal of Pharmaceutics-X 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）103 篇已发表文章登记的日期，投稿到接收的中位数为 72 天（四分位 54–95 天）；投稿社区反馈的平均审稿速度为约 17 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
International Journal of Pharmaceutics-X 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 133 位编委中，中国大陆 7 位（约 5%）；人数最多的国家是 美国（24 位）、英国（21 位）、意大利（14 位）。统计按编委会页面列出的机构国家计，仅供参考。
International Journal of Pharmaceutics-X 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，International Journal of Pharmaceutics-X 被 SCIE、Scopus、DOAJ 收录。期刊官网自述还被 PMC、PubMed 收录，该清单未与各数据库逐一核对。
International Journal of Pharmaceutics-X 是开放获取期刊吗？版面费多少？
International Journal of Pharmaceutics-X 为完全开放获取。APC 约 2,660 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。